Advancing cystic fibrosis treatment: investigational agents on the horizon Cystic fibrosis (CF) treatment has been transformed by CF transmembrane conductance regulator (CFTR) modulator therapies, yet significant gaps remain for those with non-responsive or modestly respo...

Our new paper has been published: "Advancing cystic fibrosis treatment:
investigational agents on the horizon"
in Expert Opinion in Pharmacotherapy 👨‍🔬🧬🔬🧫 💊

#cysticfibrosis #CFTR #CFTRmodulator #noveltherapeutics #precisionmedicine #pharmacology #genetherapy

www.tandfonline.com/doi/full/10....

The #BindraLab focuses on developing novel
anti-cancer therapeutics for a wide range of solid tumors. Watch as @ranjitbindra.bsky.social describes their research on #DNArepair, #cancermetabolism, and #noveltherapeutics.
youtu.be/_3qQu_SK8TA
@yaleschoolofmed.bsky.social

Recent developments in cystic fibrosis drug discovery: where are we today? The advent of variant-specific disease-modifying drugs into clinical practice has provided remarkable benefits for people with cystic fibrosis (PwCF), a multi-organ life-limiting inherited disease....

Our new paper has been published: "Recent developments in cystic fibrosis drug discovery: where are we today?"
in Expert Opinion in Drug Discovery Taylor & Francis 👨‍🔬🧬🔬🧫 💊

#cysticfibrosis #CFTR #CFTRmodulator #noveltherapeutics #precisionmedicine
#multiomics

www.tandfonline.com/eprint/RNWZS...

Sage Journals: Discover world-class research Subscription and open access journals from Sage, the world's leading independent academic publisher.

Our new paper has been published: "Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor" in Therapeutic Advances in Respiratory Disease 👨‍🔬🧬🔬🧫 💊
#cysticfibrosis #CFTR #CFTRmodulator #noveltherapeutics #precisionmedicine

journals.sagepub.com/doi/10.1177/...

A quick reminder to register for Lunch+Learn on Feb 27 at with Dr. Anne Zemella from #Fraunhofer #IZIBB!

#Potsdam #SciencePark #novelTherapeutics

Global Functional Genomics Reveals GRK5 as a Cystic Fibrosis Therapeutic Target Synergistic with Current Modulators Cystic Fibrosis (CF) is a life-shortening disease affecting >160,000 individuals worldwide predominantly with respiratory symptoms. About 80% of individuals with CF have the p.Phe508del variant that c...

Our new paper has been published: "Global Functional Genomics Reveals GRK5 as a Cystic Fibrosis Therapeutic Target Synergistic with Current Modulators" in @cp-iscience.bsky.social 👨‍🔬🧬🔬🧫 💊
#cysticfibrosis #CFTR #FunctionalGenomics #noveltherapeutics #precisionmedicine www.cell.com/iscience/ful...